U.S. markets close in 4 hours 5 minutes
  • S&P 500

    3,920.74
    +9.00 (+0.23%)
     
  • Dow 30

    31,557.35
    +56.67 (+0.18%)
     
  • Nasdaq

    11,594.41
    -13.21 (-0.11%)
     
  • Russell 2000

    1,779.86
    +14.12 (+0.80%)
     
  • Crude Oil

    109.21
    +1.59 (+1.48%)
     
  • Gold

    1,824.70
    -5.60 (-0.31%)
     
  • Silver

    21.27
    +0.15 (+0.71%)
     
  • EUR/USD

    1.0606
    +0.0047 (+0.45%)
     
  • 10-Yr Bond

    3.1920
    +0.0670 (+2.14%)
     
  • GBP/USD

    1.2304
    +0.0034 (+0.28%)
     
  • USD/JPY

    135.2960
    +0.1260 (+0.09%)
     
  • BTC-USD

    20,797.21
    -530.15 (-2.49%)
     
  • CMC Crypto 200

    452.54
    -9.26 (-2.00%)
     
  • FTSE 100

    7,258.32
    +49.51 (+0.69%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Insiders who bought this year lost US$12k as DICE Therapeutics, Inc. (NASDAQ:DICE) sheds US$104m in value

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Insiders who bought US$102k worth of DICE Therapeutics, Inc.'s (NASDAQ:DICE) stock at an average buy price of US$17.00 over the last year may be disappointed by the recent 15% decrease in the stock. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$90k, which is not what they expected.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for DICE Therapeutics

DICE Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Director James Scopa for US$102k worth of shares, at about US$17.00 per share. That means that an insider was happy to buy shares at above the current price of US$14.99. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was James Scopa.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

DICE Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. DICE Therapeutics insiders own about US$36m worth of shares. That equates to 6.2% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

What Might The Insider Transactions At DICE Therapeutics Tell Us?

The fact that there have been no DICE Therapeutics insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. Insiders do have a stake in DICE Therapeutics and their transactions don't cause us concern. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that DICE Therapeutics has 4 warning signs (1 is a bit concerning!) that deserve your attention before going any further with your analysis.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.